ABSTRACT Frequency-and voltage-dependent modification of drug-induced inhibition of maximal upstroke velocity of the action potential (Vmax) by the combined administration of two class I antiarrhythmic drugs was studied in canine Purkinje fibers, taking depression of upstroke velocity as an indicator of sodium channel blockade. The kinetics of onset of drug-induced Vmax depression and the time course of Vmax recovery were studied after exposure to therapeutic concentrations of tocainide (50 ,uM) and quinidine (5 ,uM) both singly and in combination. The rate constant for onset of block during a drive train at a cycle length of 600 msec was 0.95 ± 0.32 pulses in the presence of tocainide and 5.61 ± 0.50 pulses in the presence of quinidine. The magnitude of block was three times greater with quinidine than with tocainide. The magnitude of block produced by the combination was no greater than that produced by quinidine alone and may be partly due to abbreviation of action potential duration by tocainide. Onset of block in the presence of the combination was best fitted by a double exponential with rate constants of 0.88 ± 0.19 and 6.47 ± 1.36 pulses. Vmax recovery after termination of a rapid train of impulses was delayed by both drugs. Poststimulation recovery from either tocainide-or quinidine-induced block was characterized by a single time constant (1.04 ± 0.49 and 4.81 ± 0.76 sec, respectively), while that of the combination was characterized by two time constants (0.43 ± 0.22 and 5.94 ± 0.56 sec), presumably corresponding to dissociation of each drug from the sodium channel receptor. The mixture of the two drugs produced a large depression of Vmax of early diastolic premature responses without producing much further depression of Vmax than that produced by quinidine alone at longer coupling intervals. The time constant of recovery from tocainideinduced block was greatly dependent upon membrane potential. After steady-state changes in frequency, the combination produced a greater depression of Vmax at rapid heart rates compared with that produced by quinidine alone, but abbreviated action potential duration more at slower heart rates. Addition of tocainide to fibers equilibrated with quinidine shifted the Vmax-membrane potential relationship to more hyperpolarized potentials, resulting in greater depression of Vmax at more depolarized membrane potentials with little or no additional depression of Vmax at more negative membrane potentials. The results provide a rationale for a possible enhanced antiarrhythmic efficacy of a combination of two class I drugs that have different kinetics of interaction with the sodium channel. Circulation 76, No. 2, 427-441, 1987. A DECREASE in the maximal upstroke velocity of the action potential (Vmax) leading to a decrease in conduction velocity is characteristic of the action of class I antiarrhythmic drugs. It is now recognized that these drugs have fairly complex effects on myocardial conduction via their modulated effects on sodium channels. 1-3 Sodium-channel blockade by class I antiar- 
A DECREASE in the maximal upstroke velocity of the action potential (Vmax) leading to a decrease in conduction velocity is characteristic of the action of class I antiarrhythmic drugs. It is now recognized that these drugs have fairly complex effects on myocardial conduction via their modulated effects on sodium channels. 1-3 Sodium-channel blockade by class I antiar-rhythmic drugs is modulated by the rate of use of the channel. Rapid trains of action potentials or depolarizing pulses will enhance channel block above the basal (resting) level. After such conditioning trains channel block relaxes back to the basal level with widely differing time constants. This rate of unblocking, which is dependent on drug structure and its associated molecular weight and lipid solubility, helps determine what action potential frequencies an excitable cell can follow during drug treatment.4'5 Drugs of low molecular weight and high lipid solubility (e.g., lidocaine) tend to have rapid rates of unblocking.5'6 Such drugs would tend to show relative selectivity for depressing early 427 premature impulses or those elicited at rapid rates. Drugs with slower rates of unblocking (e.g., quinidine) would tend to be more nonselective in their depressant effects over a relatively wide range of stimulation frequencies or premature intervals. Hondeghem and Katzung2 '7 have suggested that a combination of two class I agents with different rates of unblocking, such as lidocaine and quinidine, might provide a more effective depression of early premature impulses or those elicited at rapid heart rates than either drug alone while not depressing conduction at normal heart rates beyond that produced by the drug with slower kinetics.
Such a combination may be desirable for the treatment of reentrant arrhythmias. In fact, Duff et al. 8 showed that a combination of mexiletine and quinidine was more effective against ventricular arrhythmias than either drug alone.
Tocainide is an orally active lidocaine congener. If this drug interacts with the sodium channel in a manner similar to that of lidocaine, then a combination of tocainide and quinidine might be a rational approach for the long-term control of reentrant ventricular arrhythmias. Furthermore, tocainide might also be beneficial in preventing some of the toxic manifestations associated with quinidine therapy by preventing quinidine-induced prolongation of repolarization. To gain further insight into the interaction between these two drugs, we investigated the kinetics of onset of druginduced development of block during the action potential and the time course of recovery from block during diastole in canine Purkinje fibers exposed to therapeutic concentrations of tocainide and quinidine both singly and in combination. The dependence of sodiumchannel block on stimulation rate and diastolic membrane potential was also determined.
Methods
Mongrel dogs of both sexes were anesthetized with sodium pentobarbital (30 mg/kg) and their hearts were removed via a left thoracotomy. Both ventricles were thoroughly flushed with chilled, oxygenated Tyrode's solution. Purkinje fibers with small pieces of attached ventricular muscle were quickly excised and pinned to a Sylgard block at the bottom of a tissue bath (8 ml capacity) and continuously perfused at a rate of 10 to 12 ml/min with modified Tyrode's solution aerated with 95% 02-5% CO2. Our standard Tyrode's solution contained (in mM): NaCl, 119.0; KCl, 4.0; CaCl2 1.8; MgCl2, 0.5; NaHPO4, 0.9; dextrose, 5.5; and NaHCO3, 25 . pH of the solution was 7.33 + 0.03. The temperature was maintained at 37 ± 0.2°C.
We used small, free-running intertrabecular Purkinje fiber bundles (length < 5 mm) with attached ventricular muscle. These preparations displayed minimal diastolic depolarization and provided stable membrane potentials more negative than -80 mV during prolonged periods of quiescence. Preparations that displayed automaticity were not used.
The preparations were stimulated with rectangular pulses through bipolar tungsten To study the rate of development of block with drive, the preparations were driven by 45 beat trains at an interstimulus interval of 600 msec. Rest periods between trains of stimuli were long enough to ensure full recovery from rate-dependent effects. Rate of decline of Vmax during the stimulus train and the magnitude of rate-dependent block are dependent on the interstimulus interval within the train. The magnitude of block was greater and the rate of onset of block was faster with decreases in the interstimulus interval with both tocainide and quinidine. This reflects the well-known use dependence of drug action. We chose an interstimulus interval of 600 msec because, in the presence of quinidine, the first action potential of the train is so prolonged (see figure 5 ) that if we had used shorter interstimulus intervals, the second action potential of the train would have occurred during the repolarization phase of the first response, resulting in voltage dependent depression of Vmax.
Thus, in all preparations, an interstimulus interval of 600 msec was used so that comparisons between drugs and the combination could be made.
To determine the recovery of Vmax from block, test pulses were introduced at varying diastolic intervals after a stimulus train had produced a steady level of block. The onset of diastole was defined as that time when repolarization had returned to the maximum diastolic potential. After each test pulse, there was a 20 sec quiescent interval followed by another stimulus train. Test pulses were initially introduced during phase 3 of the last action potential of the train and then progressively later in the cycle. Initially, the test intervals were increased in small steps and then in progressively larger steps. The steps ranged from 10 to 5000 msec. Each recovery curve comprised at least 50 points.
To study drug effect on steady-state sodium inactivation, preparations were stimulated at cycle lengths of 5 sec under control conditions and 10 to 20 sec in the presence of drugs. Cycle lengths longer than 20 sec could not be studied because of spontaneous activity. The fibers were then exposed to progressively higher potassium concentrations in 1 to 2 mM steps until the preparations stopped responding. Each potassium concentration was applied until steady-state effects on Vmax were observed. The preparations were then returned to a 2.7 mM potassium Tyrode's solution and exposed to a second intervention and the potassium concentrations were again increased in l CIRCULATION 428 to 2 mM steps as before. During alterations of the potassium concentration, Vmax and membrane potential were recorded on-line every 5 sec.
Tocainide used was tocainide hydrochloride generously supplied by Astra Pharmaceuticals. Quinidine used was quinidine sulfate dihydrate obtained from J. T. Baker Chemicals. The drugs were added to Tyrode's solution made up from refrigerated stock solutions. Concentrations refer to the concentrations of the base. Therapeutic concentrations of both drugs were used, 5 ,uM (1.6 ,ug/ml) of quinidine and 50 ,uM (9.6 ,ug/ml) of tocainide. The concentration of quinidine that we have used is lower than that used in most previous studies in vitro. Plasma quinidine concentrations in patients receiving therapeutic doses have been reported recently to range between 1 and 7 zug/ml.'0 11 Since the drug is 70% to 80% protein bound the free drug concentration in plasma is only 20% to 30% of that measured by conventional assay techniques. Therefore, when the drug is studied in the tissue bath with the use of protein-free superfusates, concentration of drug should be in the range of 0.2 to 2 gg/ml. The TABLE 1 form at the slower digitizing rate, which ranged from 0.6 to 1 msec, was used to determine action potential duration. Take-off potential, maximum diastolic potential, action potential amplitude (AMP), Vmax, membrane potential at which Vmax occurred (V), and action potential duration (APD) at the 50%, 75%, and 95% levels of repolarization were measured simultaneously on-line. By measuring both take-off and maximum diastolic potentials, we were able to detect the extent of any diastolic depolarization that may have occurred. In some experiments, we measured activation time, i.e., the time from the beginning of the stimulus pulse to Vmax. Where figure 1 . APD was abbreviated at all cycle lengths in the presence of the combination. The greatest absolute difference in duration between short and long cycle lengths was apparent at the 95% level of repolarization. However, similar relative changes were apparent at the 75% and 50% levels of repolarization (not shown).
The rate of onset of block in the presence of quinidine alone was much slower when compared with that in tocainide, while the magnitude of block was greater (table 2) . This concentration of quinidine produces no membrane depolarization, only a small amount of tonic block, but marked use-dependent block in fully polarized tissue. Figure 4 compares the rate of development of block for quinidine alone versus a combination of quinidine and tocainide in a preparation in which it was possible to maintain impalement during control conditions and Pulse Number FIGURE 5. Rate-dependent effects on APD at the 95% level of repolarization in the presence of quinidine versus the combination. Data were obtained from the same preparation as in figure 4 . Under all conditions, the duration of the first action potential of the train was prolonged. Shortening of duration during the train followed a double exponential decline, with rate constants of 0.32 and 9.1 pulses under drug free condition ( + ), 1.14 and 8.71 pulses after exposure to quinidine (A), 0.89 and 9.34 pulses after exposure to the combination (0), and 0.95 and 7.67 pulses after reexposure to quinidine alone (A Since it took at least 1 hr to achieve steady state effects with quinidine and a substantial amount of time to generate a recovery curve with each drug, it was not possible to maintain impalement in the same cell long enough to study both drugs and their combination in a given preparation. Thus, the effects of tocainide alone were assessed in one group of experiments and those of quinidine versus the combination were assessed in another group of experiments. We could not accurately determine recovery time constants under drug-free conditions because Vmax had already attained its maximal value at the time when repolarization was complete. However, when this measurement was made during the terminal phase of repolarization a time constant of 26.14 ± 10.45 msec (mean + SD, n = 7) was obtained. This value for control recovery time constant (although it includes both voltage-and time-dependent recovery) is compa- Dicstolic Interva( (sec) FIGURE 6 . Time course of recovery from block in the presence of 50 ,uM of tocainide. Top, Vmax versus diastolic interval, where zero diastolic interval is defined as return of repolarization to the maximum diastolic potential. Bottom, Activation time;
i.e., the time from the beginning of the stimulus pulse to Vmax. Although the activation time is a measure of excitability and conduction, it does provide some approximation of drug effect on conduction. Recovery from block in the presence of drug was assessed when the extracellular potassium concentration was 4, 6, and 8 mM. The curves represent nonlinear least squares fits of the data. Under drug-free conditions, the recovery time constant was 27 msec. Under tocainide and a 4 mM K + concentration, the recovery time constant was 1.08 sec and the membrane potential was 87.0 mV. figure 6 .
The time constant for recovery of Vmax averaged 1.04 ± 0.49 sec (mean ± SD, n = 8). Early diastolic block, defined as the magnitude of Vmax depression at zero diastolic interval compared with recovery Vmax, averaged 10.34 ± 3.10% (mean ± SD, n=8).
Both the time constant for recovery of Vmax and the magnitude of early diastolic block produced by tocainide was highly dependent on membrane potential (figures 6 and 7) . The less negative the membrane potential the slower was the recovery time constant and the greater the early diastolic block, suggesting that at reduced membrane potentials, a greater number of sodium channels were blocked and drug unbinding was slower. There was approximately a sixfold difference in the time constant for recovery of Vmax and approximately a fourfold difference in the magnitude of early diastolic block over approximately a 15 mV range of membrane potentials. the combination was characterized by two time constants. The mixture of the two drugs produced a much larger depression of Vmax of early premature responses compared with that by quinidine. There was also additional depression of Vmax (8.5%) at long coupling intervals. However, there was no additional depression of activation time at these same long intervals. The degree of depression of Vmax at long coupling intervals after exposure to the combination was variable, ranging from minimal block to about 10% block. However, the depression of early responses was always consistently greater. During recovery from drug-induced frequency-dependent block, changes in activation time were found to be reciprocably related to changes in Vmax Membrane Potential (-mV) FIGURE 7 . 
sistently shifted the Vmax curves to more negative potentials, suggesting an interference with sodium inactivation. This effect developed at stimulation rates at which tocainide shows no frequency-dependent effects. Figure 9 , A shows that under control conditions, half inactivation occurred at -71 mV. Tocainide, 50 ,M, shifted the steady-state inactivation curve along the voltage axis to more hyperpolarized potentials, half inactivation now occurring at -75 mV. The peak Vmax obtainable was diminished slightly by tocainide suggesting that there was a small degree of resting block (less than 3%) at membrane potentials more negative than -90 mV. Tocainide shifted the curve an average of 3.25 mV (n=2).
In 9, B) . Addition of tocainide to fibers equilibrated with quinidine produced a shift similar to that produced by tocainide alone in control fibers, as seen in figure 9 , A. In the presence of the combination, there was a greater depression of Vmax, particularly at more depolarized membrane potentials. The combination shifted the curve an average of 3.15 + 0. 1 1 mV (n = 4).
Discussion
In a beating heart, interaction of local anesthetic type drugs with the sodium channel receptor changes dynamically throughout the cardiac cycle. During an action potential, sodium channels cycle through three different states, rested, open and inactivated, as described by Hodgkin and Huxley.20 Hondeghem and Katzung' proposed that each one of these three states can interact with antiarrhythmic drugs and that drugassociated channels also rotate between the three states but they behave as if their voltage dependence is shifted to more hyperpolarized potentials.
Most class I antiarrhythmic drugs have a very low affinity for the receptor site when the channel is in the rested state, but have a high affinity for the receptor when the channel is open or inactivated.2 Thus, block develops during each action potential and then dissipates when the channels return to the rested state at the beginning of diastole. The rate of drug dissociation during diastole varies for different clinically effective class I drugs.21 Thus, sodium-channel block evoked by these drugs is characterized by a pronounced dependence on stimulation rate. Our results suggest that for quinidine, the rate of drug dissociation at normal diastolic potentials is slow enough (4.0 to 6. 1 sec) so that block does not fully dissipate between beats throughout the clinical range of heart rates. Similar time constants of dissociation for quinidine have been obtained by others.22 24 For tocainide, the rate of drug dissociation in fully polarized cells is much faster (0.5 to 1.7 sec). Thus, in the presence of tocainide, a substantial amount of block can dissipate between beats at slow heart rates. Similar time constants of dissociation for tocainide were obtained by Gintant et al.25 in Purkinje fibers, and by Courtney26 in guinea pig papillary muscles. Oshita et al. ,27 using two different experimental protocols, found two components of recovery for tocainide in guinea pig papillary muscle. It is unlikely that their first component is recovery from drug effect since they conducted their study at a basic cycle length of 4000 msec, which is unlikely to produce any degree of block in the presence of tocainide. Thus, there could not have been any block from which to recover. The first component is more likely recovery from slow inactivation, as described by Clarkson et A drug such as tocainide that selectively blocks conduction in depolarized tissue and also shortens APD can also facilitate induction of reentrant arrhythias.35,36 The advantage of combining such a drug with quinidine is that selective depression of conduction in depolarized tissue is combined with prolongation of refractory period in fully polarized tissue.
The combination may also have beneficial effects in the treatment of arrhythmias due to enhanced automaticity. A combination of tocainide and quinidine suppresses Purkinje fiber automaticity much more than quinidine alone. * The escape intervals following a train of stimuli were very much longer in the presence of the combination compared with those with quinidine alone.
Tocainide may enhance the antiarrhythmic action of quinidine while at the same time preventing quinidineinduced toxicity. A quinidine-induced increase in the corrected QT interval, particularly in the presence of slow heart rates and a low potassium concentration, has been associated with torsades de pointes-type of arrhythmias. Roden and Hoffman37 have shown that at cycle lengths greater than 4000 msec in low extracellular potassium, quinidine produced early afterdepolarizations in canine Purkinje fibers. Early afterdepolarizations were eliminated by interventions that abbreviated the APD. They suggested that this form of triggered activity may play a role in quinidine induced torsades de pointes. We also found that tocainide, by preventing the marked prolongation of APD by quinidine, particularly at slow heart rates and low potassium concentrations, abolished early afterdepolarizations produced by quinidine ( figure 10 ). Hence, a combination of tocainide and quinidine might be expected to prevent the development of quinidine-induced torsades de pointes arrhythmias.
Thus, the present study provides a rationale for a possible enhanced antiarrhythmic efficacy of a combination of two another lidocaine congener, mexiletine. Although tocainide has rapid recovery kinetics compared with quinidine, its kinetics are slower than those of lidocaine or mexiletine. This is probably related to tocainide's poor lipid solubility and thus more restricted access to the receptor in the channel.5
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